Article Text
Statistics from Altmetric.com
Parkinson's disease is a progressive neurodegenerative disorder characterised by slowness of initiation of, and a progressive reduction in, the speed and amplitude of sequential movements (ie, motor decrement or decay), with muscular rigidity and a coarse slow pill rolling rest tremor. The pathological signature most frequently associated with this clinical picture is severe loss of pigmented neurons in the ventrolateral tier of the pars compacta of the substantia nigra with the presence of distinctive α synuclein immunoreactive inclusions in surviving nigral neurons (Lewy bodies).
Epidemiology
In the UK:
▶. prevalence about 1/800, annual incidence 1/8000
▶. 1% of people over the age of 65 years are affected
▶. a general practitioner will have three to four patients at any one time
▶. median age of onset is 60 years, with a slight male preponderance
▶. disease onset to death is about 15 years, twice the number of observed to expected deaths (standardised mortality ratio 2:1).
The disorder is no respecter of race or creed Literary and historical precedents to Parkinson's seminal description suggest it is unlikely to be a post-industrial disease. In common with other neurodegenerative diseases, increasing age is the major risk factor although 15% of cases present before the age of 45 years and the incidence may decrease somewhat in the ninth decade of life. Genetic factors are now considered to significantly increase risk.
Habitual non-cigarette smokers are twice as likely to develop the illness as smokers and there may also be a mildly increased risk to men who do not take any caffeine, perhaps related to dopamine's role in reward pathways, rather than due to a protective effect of nicotine or coffee. Loose associations with rural living, middle age, obesity and lack of exercise, well water ingestion and pesticide exposure have also been reported. Environmental toxins such as …
Footnotes
-
Competing interests AL has received honoraria for advisory boards from Roche, Novartis, Orion, Boehringer Ingelheim, GSK, Britannia Pharmaceuticals, Solvay and Medtronic and has a consultancy agreement with Britannia Pharmaceuticals.
-
Provenance and peer review Commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Improving the diagnostic accuracy in parkinsonism: a three-pronged approach
- Parkinson's disease: chameleons and mimics
- Parkinson’s disease: clinical features and diagnosis
- Changes in diagnosis with follow-up in an incident cohort of patients with parkinsonism
- Is it Parkinson’s disease, and if not, what is it?
- DIAGNOSIS AND MANAGEMENT OF ATYPICAL PARKINSONIAN SYNDROMES
- Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes
- Diagnosis and pharmacological management of Parkinson’s disease: summary of SIGN guidelines
- The role of DAT-SPECT in movement disorders
- How useful is [123I]β-CIT SPECT in clinical practice?